| Aug 13 |
Achieve Life Sciences GAAP EPS of -$0.25 misses by $0.01
|
| Aug 13 |
Achieve Life Sciences Reports Financial Results for Second Quarter 2024 and Provides Corporate Update
|
| Jul 31 |
Achieve gets FDA breakthrough status for vaping cessation drug
|
| Jul 31 |
Achieve Life Sciences Announces FDA Grants Breakthrough Therapy Designation to Cytisinicline for the Treatment of E-Cigarette or Vaping Nicotine Dependence
|
| Jul 29 |
Achieve Life Sciences announces $20M loan refinancing
|
| Jul 29 |
Achieve Life Sciences Announces $20M Loan Refinancing with Silicon Valley Bank
|
| Jul 25 |
Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 13, 2024
|
| Jul 15 |
Milestone Pharmaceuticals Refreshes Board of Directors
|
| Jul 9 |
Achieve Life Sciences to Present at JonesHealthcare Seaside Summit 2024
|
| Jul 5 |
With 64% ownership of the shares, Achieve Life Sciences, Inc. (NASDAQ:ACHV) is heavily dominated by institutional owners
|
